OncoHost announced it has been named a Gold Winner in the 2025 Merit Awards for Healthcare, recognized as the Technology Solution of the Year.
The Merit Awards for Healthcare celebrate organizations delivering breakthrough technologies that meaningfully advance patient care. OncoHost earned top honors for its PROphet platform, an AI-powered, plasma-proteomics solution that predicts patient response to cancer therapy using a single pre-treatment blood sample.
Ofer Sharon, MD, CEO of OncoHost said in a press release, “Our goal is to provide oncologists with clear, actionable insights that support more confident and informed treatment decisions from day one. We appreciate this acknowledgment of our team’s ongoing work to advance precision oncology.”
The PROphet platform analyzes more than 7,000 proteins from a patient’s plasma, leveraging proprietary machine-learning algorithms to generate individualized predictive models for overall survival and progression-free survival. The platform’s first commercial offering, PROphetNSCLC, is the only AI-based blood test available today that predicts patient outcomes to first-line immunotherapy in metastatic non-small cell lung cancer (NSCLC).
With launches of PROphetRCC and PROphetMELANOMA underway, and expanded development into additional tumor types, OncoHost is rapidly scaling its platform to support broader, indication-agnostic clinical decision-making. The company is also advancing PROphetirAE, designed to predict severe immune-related adverse events prior to therapy initiation.
Read OncoHost's announcement here
